This will add to the global literature of epidemiological data for CML and aid clinician awareness as early diagnoses in the chronic phase with low BCR–ABL1 levels and blast counts will increase the likelihood of patients’ successful response to treatment [16]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.